Molecule Information

General Information of the Molecule (ID: Mol04417)

• Name: CD109 antigen (CD109) ,Homo sapiens
• Synonyms: 150 kDa TGF-beta-1-binding protein; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 7; Platelet-specific Gov antigen; p180; r150; CD_antigen=CD109
• Molecule Type: Protein
• Gene Name: CD109
• Gene ID: 135228
• Sequence:
  MQGPPLLTAAHLLCVCTAALAVAPGPRFLVTAPGIIRPGGNVTIGVELLEHCPSQVTVKA
  ELLKTASNLTVSVLEAEGVFEKGSFKTLTLPSLPLNSADEIYELRVTGRTQDEILFSNS
  T RLSFETKRISVFIQTDKALYKPKQEVKFRIVTLFSDFKPYKTSLNILIKDPKSNLIQQ
  WL SQQSDLGVISKTFQLSSHPILGDWSIQVQVNDQTYYQSFQVSEYVLPKFEVTLQTPL
  YCS MNSKHLNGTITAKYTYGKPVKGDVTLTFLPLSFWGKKKNITKTFKINGSANFSFND
  EEMK NVMDSSNGLSEYLDLSSPGPVEILTTVTESVTGISRNVSTNVFFKQHDYIIEFFD
  YTTVL KPSLNFTATVKVTRADGNQLTLEERRNNVVITVTQRNYTEYWSGSNSGNQKMEA
  VQKINY TVPQSGTFKIEFPILEDSSELQLKAYFLGSKSSMAVHSLFKSPSKTYIQLKTR
  DENIKVG SPFELVVSGNKRLKELSYMVVSRGQLVAVGKQNSTMFSLTPENSWTPKACVI
  VYYIEDDG EIISDVLKIPVQLVFKNKIKLYWSKVKAEPSEKVSLRISVTQPDSIVGIVA
  VDKSVNLMN ASNDITMENVVHELELYNTGYYLGMFMNSFAVFQECGLWVLTDANLTKDY
  IDGVYDNAEY AERFMEENEGHIVDIHDFSLGSSPHVRKHFPETWIWLDTNMGYRIYQEF
  EVTVPDSITSW VATGFVISEDLGLGLTTTPVELQAFQPFFIFLNLPYSVIRGEEFALEI
  TIFNYLKDATEV KVIIEKSDKFDILMTSNEINATGHQQTLLVPSEDGATVLFPIRPTHL
  GEIPITVTALSPT ASDAVTQMILVKAEGIEKSYSQSILLDLTDNRLQSTLKTLSFSFPP
  NTVTGSERVQITAI GDVLGPSINGLASLIRMPYGCGEQNMINFAPNIYILDYLTKKKQL
  TDNLKEKALSFMRQG YQRELLYQREDGSFSAFGNYDPSGSTWLSAFVLRCFLEADPYID
  IDQNVLHRTYTWLKGH QKSNGEFWDPGRVIHSELQGGNKSPVTLTAYIVTSLLGYRKYQ
  PNIDVQESIHFLESEFS RGISDNYTLALITYALSSVGSPKAKEALNMLTWRAEQEGGMQ
  FWVSSESKLSDSWQPRSL DIEVAAYALLSHFLQFQTSEGIPIMRWLSRQRNSLGGFAST
  QDTTVALKALSEFAALMNT ERTNIQVTVTGPSSPSPVKFLIDTHNRLLLQTAELAVVQP
  TAVNISANGFGFAICQLNVV YNVKASGSSRRRRSIQNQEAFDLDVAVKENKDDLNHVDL
  NVCTSFSGPGRSGMALMEVNL LSGFMVPSEAISLSETVKKVEYDHGKLNLYLDSVNETQ
  FCVNIPAVRNFKVSNTQDASVS IVDYYEPRRQAVRSYNSEVKLSSCDLCSDVQGCRPCE
  DGASGSHHHSSVIFIFCFKLLYF MELWL
• Function: Modulates negatively TGFB1 signaling in keratinocytes.{ECO:0000269|PubMed:16754747}.
• Uniprot ID: CD109_HUMAN
• Ensembl ID: ENSG0000015653515
• HGNC ID: HGNC:21685

Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens

Type(s) of Resistant Mechanism of This Molecule

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Drug

Approved Drug(s) 3 drug(s) in total

Cisplatin

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Disease Class: Epithelial ovarian cancer [ICD-11: 2B5D.0] [1]

• Resistant Disease: Epithelial ovarian cancer [ICD-11: 2B5D.0]
• Resistant Drug: Cisplatin
• Molecule Alteration: Expression; Down-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: STAT3 signaling pathway; Activation; hsa04550
• Cell Pathway Regulation: Notch signaling pathway; Activation; hsa04330
• In Vitro Model: A2780/R cells; ovarian; Homo sapiens (Human); CVCL_4862
• Experiment for Molecule Alteration: Western blot assay
• Experiment for Drug Resistance: Cell viability assay
• Mechanism Description: We found that CD109 expression was upregulated in doxorubicin-resistant EOC cells (A2780-R) compared with that in their parental cells. CD109 plays a key role in the acquisition of drug resistance by activating the STAT3-NOTCH1 signaling axis in patients with EOC.

Doxorubicin

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Disease Class: Epithelial ovarian cancer [ICD-11: 2B5D.0] [1]

• Resistant Disease: Epithelial ovarian cancer [ICD-11: 2B5D.0]
• Resistant Drug: Doxorubicin
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: STAT3 signaling pathway; Activation; hsa04550
• Cell Pathway Regulation: Notch signaling pathway; Activation; hsa04330
• In Vitro Model: A2780/R cells; ovarian; Homo sapiens (Human); CVCL_4862
• Experiment for Molecule Alteration: Western blot assay
• Experiment for Drug Resistance: Cell viability assay
• Mechanism Description: We found that CD109 expression was upregulated in doxorubicin-resistant EOC cells (A2780-R) compared with that in their parental cells. CD109 plays a key role in the acquisition of drug resistance by activating the STAT3-NOTCH1 signaling axis in patients with EOC.

Paclitaxel

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Disease Class: Epithelial ovarian cancer [ICD-11: 2B5D.0] [1]

• Resistant Disease: Epithelial ovarian cancer [ICD-11: 2B5D.0]
• Resistant Drug: Paclitaxel
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: STAT3 signaling pathway; Activation; hsa04550
• Cell Pathway Regulation: Notch signaling pathway; Activation; hsa04330
• In Vitro Model: A2780/R cells; ovarian; Homo sapiens (Human); CVCL_4862
• Experiment for Molecule Alteration: Western blot assay
• Experiment for Drug Resistance: Cell viability assay
• Mechanism Description: We found that CD109 expression was upregulated in doxorubicin-resistant EOC cells (A2780-R) compared with that in their parental cells. CD109 plays a key role in the acquisition of drug resistance by activating the STAT3-NOTCH1 signaling axis in patients with EOC.

References

• Ref 1: CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis. Int J Mol Sci. 2023 Jun 18;24(12):10306.